<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/16513C09-7140-413B-AF1F-A7A878ADB3B9"><gtr:id>16513C09-7140-413B-AF1F-A7A878ADB3B9</gtr:id><gtr:name>CARLSBERG GROUP</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Pharmaceutical Sciences</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/16513C09-7140-413B-AF1F-A7A878ADB3B9"><gtr:id>16513C09-7140-413B-AF1F-A7A878ADB3B9</gtr:id><gtr:name>CARLSBERG GROUP</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/DB036394-9034-4494-9006-922B3027AFDA"><gtr:id>DB036394-9034-4494-9006-922B3027AFDA</gtr:id><gtr:firstName>Gerd</gtr:firstName><gtr:surname>Wagner</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0901746"><gtr:id>280636E0-44CA-47F8-908A-D803232A917C</gtr:id><gtr:title>A New and Simple Screening Tool for Antibacterial Drug Discovery</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0901746</gtr:grantReference><gtr:abstractText>During a certain time period in the 70s and 80s, infections had perhaps been regarded as a medical ?problem solved?, at least in the developed world. However, many bacterial pathogens are now back with a vengeance ? and our lines of defence are weak. Despite the emergence of multidrug-resistant, bacterial pathogens like MRSA (methicillin-resistant S. aureus) and the resurgence of killers such as tuberculosis, only 13 new antibiotics have entered the market in the past decade. And there isn?t much else in the pipeline either.
In this project, we are developing tools to explore a new strategy for throwing a ?spanner? in the bacterial works. We are looking at a large class of bacterial enzymes ? part of the machinery bacteria use to cover themselves with a protective coat ? which has not previously been explored for antibacterial drug development. We are developing tools to explore a new strategy for punching holes in the protective coat of bacteria, which may ultimately lead to the development of novel antibacterial agents.</gtr:abstractText><gtr:technicalSummary>The emergence of multidrug-resistant, bacterial pathogens like MRSA (methicillin-resistant S. aureus), the resurgence of infectious diseases such as tuberculosis, which had been close to eradication only a few decades ago, and the growing threat from bioterrorism have created an urgent need for the development of novel antibacterial therapeutics. In this project, a simple inhibitor screening assay will be developed and validated, to explore the potential of glycosyltransferases involved in the biosynthesis of the gram-negative cell wall as novel targets for antibacterial drug discovery.</gtr:technicalSummary><gtr:fund><gtr:end>2012-11-15</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-11-16</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>195967</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Hygiene and Tropical Medicine (LSHTM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Pathogen Molecular Biology</gtr:department><gtr:description>London School of Hygiene</gtr:description><gtr:id>5C1DEA3B-E2B8-42EA-AE4D-9E26A46AF347</gtr:id><gtr:impact>The characterisation of our chemical probes is ongoing and involves a chemistry/enzymology team (us) and a microbiology team (LSHTM). The collaboration has allowed us to submit a joint project to the BBSCR London Interdisciplinary PhD consortium.</gtr:impact><gtr:outcomeId>H8ramserK96-1</gtr:outcomeId><gtr:partnerContribution>carried out biological experiments with chemical probes, inhibitors and assays provided by us</gtr:partnerContribution><gtr:piContribution>provided chemical probes, inhibitors and assays for the investigation of bacterial glycosylation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Carlsberg Group</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:department>Carlsberg Research Centre</gtr:department><gtr:description>Carlsberg Laboratory</gtr:description><gtr:id>A14DF070-0CF6-4404-AE59-CA63F8FB45EB</gtr:id><gtr:impact>This collaboration is multidisciplinary: Wagne group - synthetic and medicinal chemistry, Palcic group - biological assays. Results from this ongoing collaboration have contributed to two published articles (Nature Chem. Biol. 2010, 6, 321-323, ChemBioChem 2010, 11, 1392-1398), with another one submitted to J Med Chem currently in revision.</gtr:impact><gtr:outcomeId>bW6pCMeexVe-1</gtr:outcomeId><gtr:partnerContribution>Monica Palcic at the Carlsberg has carried out biological tests with compounds we have developed in this project, She has also provided us with research materials (e.g. plasmids for enzymes) and has hosted the visit of a postodoctoral researcher from my group for training in protein expression and enzyme assays.</gtr:partnerContribution><gtr:piContribution>We have provided chemical compounds for evaluation in biological assays.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Nuffield Foundation Science Bursary Programme</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>8508B5C8-6F43-4038-A70E-728FC4A7F9FB</gtr:id><gtr:impact>A 6th form student visited the laboratory for 4 weeks, supported by a Nuffield Foundation Science Bursary, to gain research experience by participating in one of my MRC-funded research projects.

I will continue to participate as a partner in the Nuffield Foundation Science Bursary Programme for Schools &amp;amp; Colleges.</gtr:impact><gtr:outcomeId>okSiDGSgwmu</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Bugs vs Man: Who's winning now? - KCL Christmas Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>4608490C-BB85-422E-9C6F-E713FCE0E4C1</gtr:id><gtr:impact>I gave a talk entitled &amp;quot;Bugs vs Man: Who's winning now?&amp;quot; on the current status of antibiotics, antibiotics resistance, and work in my lab in these areas. The talk was for an audience of 6th formers as part of the annual Christmas Lecture of the King's College School of Natural and Mathematical Sciences. Ca 100 pupils registered for this event.

One of the purposes of the Christmas Lectures is to stimulate interest among pupils in the sciences and motivate them to study for a HE degree at the College.</gtr:impact><gtr:outcomeId>Er7qp8RGpPP</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1520</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Biomedical Vacation Scholarship</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>EF558B85-918E-4339-B027-3056EACAD636</gtr:id><gtr:outcomeId>jv4HrzR1KtB</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2120</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>British Society for Antimicrobial Chemotherapy vacation scholarship</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>British Society for Antimicrobial Chemotherapy</gtr:fundingOrg><gtr:id>88FD0088-47B0-40D6-8319-5DBB71D49108</gtr:id><gtr:outcomeId>546476401d76f6.62190548</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>development of fluorescent nucleotides and nucleotide-conjugates for applications in protein binding assays, e.g. for small molecular inhibitor screening</gtr:description><gtr:grantRef>G0901746</gtr:grantRef><gtr:id>C5E3B492-79D6-4D91-8831-45A5145A3863</gtr:id><gtr:impact>this IP forms part of the ongoing collaboration with Ludger Ltd</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56e00b33e44d90.30878524</gtr:outcomeId><gtr:patentId>W02011/051733</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>DERIVATIVES OF URIDINE PHOSPHATE AND THEIR USES IN PROTEIN BINDING ASSAYS</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have prepared and biologically evaluated a novel class of inhibitors and fluorescent probes for glycosyltransferases. In future, these novel tools will be used for biological studies on this important class of enzymes, specifically for the development of glycosyltransferase bioassays.</gtr:description><gtr:id>4A01FE60-0FCA-46D7-91C7-704AF3DB1668</gtr:id><gtr:impact>Discovery of a novel class of glycosyltransferase inhibition (manuscrit submitted to Nature Chemical Biology, currently under revision).</gtr:impact><gtr:outcomeId>7D570968663</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>glycosyltransferase inhibitors and fluorescent probes</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A series of ca 10 new fluorescent probes for glycosyltransferases (GTs) has been prepared. The biological evaluation of the new materials as potential substrate analogues or inhibitors is ongoing.</gtr:description><gtr:id>9AED63FF-3F15-4E13-B5FC-F2A2F0FD72CC</gtr:id><gtr:impact>The new fluorescent probes are currently under investigation in recombinant and cellular assays, in collaboration with other research groups (Palcic/Copenhagen, Page/London)</gtr:impact><gtr:outcomeId>b7rLbA3xExU</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>GT fluorescent probes</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>ABAF4128-8BC8-45D7-868E-BA2BCB11789C</gtr:id><gtr:title>Interaction of Neisseria meningitidis Group X N-acetylglucosamine-1-phosphotransferase with its donor substrate.</gtr:title><gtr:parentPublicationTitle>Glycobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1645712d699929b197c3d53ed548d969"><gtr:id>1645712d699929b197c3d53ed548d969</gtr:id><gtr:otherNames>Ming SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0959-6658</gtr:issn><gtr:outcomeId>5a679702e32379.95820960</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9704D830-C5FB-40D0-9C5C-6B9F232FAF9A</gtr:id><gtr:title>Base-modified donor analogues reveal novel dynamic features of a glycosyltransferase.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1c5f65acec2ba7160f33a493dc848a6"><gtr:id>b1c5f65acec2ba7160f33a493dc848a6</gtr:id><gtr:otherNames>J?rgensen R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>UzHDHQZezR1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4200BFD1-9491-4255-8F19-6CBB83E82280</gtr:id><gtr:title>Novel UDP-GalNAc Derivative Structures Provide Insight into the Donor Specificity of Human Blood Group Glycosyltransferase.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6724ec3fbec2623b5961adc83df9e037"><gtr:id>6724ec3fbec2623b5961adc83df9e037</gtr:id><gtr:otherNames>Wagner GK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>56e00816883e54.80894012</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2954338E-803C-4DB5-AE25-812161EB684A</gtr:id><gtr:title>A practical glycosyltransferase assay for the identification of new inhibitor chemotypes</gtr:title><gtr:parentPublicationTitle>Med. Chem. Commun.</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56e3085fce7d3d30eff69abf7dcd3d4f"><gtr:id>56e3085fce7d3d30eff69abf7dcd3d4f</gtr:id><gtr:otherNames>Tedaldi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>54647273830ff9.28772655</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E1EEB5D-7C12-4ADB-818D-6B0BB9B16777</gtr:id><gtr:title>Exploring the role of the 5-substituent for the intrinsic fluorescence of 5-aryl and 5-heteroaryl uracil nucleotides: a systematic study.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12a99e9e43525209b857e7cb1e5708d3"><gtr:id>12a99e9e43525209b857e7cb1e5708d3</gtr:id><gtr:otherNames>Pesnot T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>Gd8bmA8WP9G</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D15523AF-264F-44C4-A0C7-1544176F3C11</gtr:id><gtr:title>One-step synthesis of novel glycosyltransferase inhibitors.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a02cf16dfa3fa6d699a45937ab36122"><gtr:id>9a02cf16dfa3fa6d699a45937ab36122</gtr:id><gtr:otherNames>Evitt A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>pm_16181_21_23125983</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>19E3642D-2B6D-43FE-8ACB-68E19EA7374D</gtr:id><gtr:title>Base-modified UDP-sugars reduce cell surface levels of P-selectin glycoprotein 1 (PSGL-1) on IL-1?-stimulated human monocytes.</gtr:title><gtr:parentPublicationTitle>Glycobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6d94f8e2088d5ea6f02ffaaf373f9c6"><gtr:id>a6d94f8e2088d5ea6f02ffaaf373f9c6</gtr:id><gtr:otherNames>Kanabar V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0959-6658</gtr:issn><gtr:outcomeId>58bc9ec6abab48.16012406</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD3E4777-6A1A-4245-BE6E-B6A2B95D7D89</gtr:id><gtr:title>Optimised chemical synthesis of 5-substituted UDP-sugars and their evaluation as glycosyltransferase inhibitors.</gtr:title><gtr:parentPublicationTitle>Carbohydrate research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/029c6cb2c6b225c7a17b671f57c937fd"><gtr:id>029c6cb2c6b225c7a17b671f57c937fd</gtr:id><gtr:otherNames>Tedaldi LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0008-6215</gtr:issn><gtr:outcomeId>pm_16181_21_23147042</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0901746</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>